DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination

被引:47
作者
Castaldello, Arianna
Brocca-Cofano, Egidio
Voltan, Rebecca
Triulzi, Chiara
Altavilla, Giuseppe
Laus, Michele
Sparnacci, Katia
Ballestri, Marco
Tondelli, Luisa
Fortini, Cinzia
Gavioli, Riccardo
Ensoli, Barbara
Caputo, Antonella
机构
[1] Univ Padua, Microbiol Sect, Dept Histol Microbiol & Med Biotechnol, I-35122 Padua, Italy
[2] Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy
[3] Univ Padua, Dept Pathol Anat & Histol, I-35122 Padua, Italy
[4] Univ Piemonte Orientale, Dept Life & Ambient Sci, Alessandria, Italy
[5] INSTM, UdR, Alessandria, Italy
[6] CNR, ISOF, I-40126 Bologna, Italy
[7] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy
关键词
biocompatible nanoparticles; HIV-1; tat; DNA vaccination; cellular responses;
D O I
10.1016/j.vaccine.2006.05.058
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Novel biocompatible core-shell cationic nanoparticles, composed of an inner hard core of poly(methylmethacrylate) (PMMA) and a hydrophilic tentacular shell bearing positively charged groups and poly(ethyleneglycol) chains covalently bound to the core, were prepared by emulsion polymerization and characterized in vitro and in vivo for DNA vaccine applications. The nanoparticles reversibly adsorbed large amounts of DNA, mainly through electrostatic interactions, preserved its functional structure, efficiently delivered it intracellularly, and were not toxic in vitro or in mice. Furthermore, two intramuscular (i.m.) immunizations (4 weeks apart) with a very low dose (1 mu g) of the plasmid pCV-tat delivered by these nanoparticles followed by one or two protein boosts induced significant antigen-specific humoral and cellular responses and greatly increased Th1-type T cell responses and CTLs against HIV-1 Tat. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5655 / 5669
页数:15
相关论文
共 70 条
[1]  
Alpar H Oya, 2005, Expert Opin Drug Deliv, V2, P829, DOI 10.1517/17425247.2.5.829
[2]   Biodegradation and biocompatibility of PLA and PLGA microspheres [J].
Anderson, JM ;
Shive, MS .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :5-24
[3]   TRANS-ACTIVATOR GENE OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-III (HTLV-III) [J].
ARYA, SK ;
GUO, C ;
JOSEPHS, SF ;
WONGSTAAL, F .
SCIENCE, 1985, 229 (4708) :69-73
[4]   Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P) [J].
Cafaro, A ;
Titti, F ;
Fracasso, C ;
Maggiorella, MT ;
Baroncelli, S ;
Caputo, A ;
Goletti, D ;
Borsetti, A ;
Pace, M ;
Fanales-Belasio, E ;
Ridolfi, B ;
Negri, DRM ;
Sernicola, L ;
Belli, R ;
Corrias, F ;
Macchia, I ;
Leone, P ;
Michelini, Z ;
ten Haaft, P ;
Buttò, S ;
Verani, P ;
Ensoli, B .
VACCINE, 2001, 19 (20-22) :2862-2877
[5]   Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients [J].
Calarota, S ;
Bratt, G ;
Nordlund, S ;
Hinkula, J ;
Leandersson, AC ;
Sandström, E ;
Wahren, B .
LANCET, 1998, 351 (9112) :1320-1325
[6]  
CAPUTO A, 1990, J ACQ IMMUN DEF SYND, V3, P372
[7]   Recent advances in the development of HIV-1 Tat-based Vaccines [J].
Caputo, A ;
Gavioli, R ;
Ensoli, B .
CURRENT HIV RESEARCH, 2004, 2 (04) :357-376
[8]   Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application [J].
Caputo, A ;
Brocca-Cofano, E ;
Castaldello, A ;
De Michele, R ;
Altavilla, G ;
Marchisio, M ;
Gavioli, R ;
Rolen, U ;
Chiarantini, L ;
Cerasi, A ;
Dominici, S ;
Magnani, M ;
Cafaro, A ;
Sparnacci, K ;
Laus, M ;
Tondelli, L ;
Ensoli, B .
VACCINE, 2004, 22 (21-22) :2910-2924
[9]   Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat [J].
Caputo, A ;
Gavioli, R ;
Altavilla, G ;
Brocca-Cofano, E ;
Boarini, C ;
Betti, M ;
Castaldello, A ;
Lorenzini, F ;
Micheletti, F ;
Cafaro, A ;
Sparnacci, K ;
Laus, M ;
Tondelli, L ;
Ensoli, B .
VACCINE, 2003, 21 (11-12) :1103-1111
[10]  
Caselli E, 1999, J IMMUNOL, V162, P5631